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Inhibitor in hemophilia and its management-A case report
Anjalin D’Souza*, Dinesh M Nayak, Annamma Kurien
Email: anjeline.d@manipal.edu

Abstract
Hemophilia is a genetic disease with a deficiency of factor VIII or IX. People with inhibitors require special care and
treatment due to complexity of the disease. Treatment is expensive due to high dose infusion and unavailability of
factor in developing countries like India. This case report focuses on role of comprehensive care and follow-up of an
adolescent with inhibitors.
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Introduction
Hemophilia is an inherited X-linked coagulation
disorder caused by deficiencies of the clotting factor
VIII (FVIII: hemophilia A) or factor IX (FIX:
hemophilia B). In India, 18,353 people are diagnosed to
have hemophilia as per the recent annual global survey
report (WFH, Annual Global Survey 2016, 2017).
Hemophilia is classified based on percentage of factor
levels as mild, moderate and severe in clinical severity.
Spontaneous bleeds are more in moderate and severe
hemophiliacs compared to people with mild hemophilia
(Phadke, 2011).
Inhibitors are the antibodies produced by the body to
fight off the foreign protein present in the treatment
product. People with severe hemophilia have got more
risk of developing inhibitors than mild and moderate
hemophilia. Inhibitors occur among 25-30% of children
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with severe hemophilia A and 1-6% of individuals with
hemophilia B. Regular testing for inhibitors should be
done among newly diagnosed people with hemophilia
between the 1st and 50th days of treatment. Check
for inhibitor at least twice a year after the 50th day
of treatment, until they have received 150-200 doses.
Continue checking for inhibitor once a year after that.
Before any major surgery also inhibitor needs to be
checked. When the person is not responding to standard
treatment usually inhibitor is suspected (WFH, 2014).
Case report
A 13-year old boy with factor VIII deficiency was
admitted with swelling of the left knee joint. He was
diagnosed with hemophilia at the age of two years and
on-demand factor replacement therapy. Initially he was
treated with skin traction, analgesics and tranexamic
acid. But the symptoms did not subside with the
treatment. Blood investigations were done to find
out the reason for not responding factor replacement
therapy. APTT value was 85.9 Sec and inhibitor screen
was positive and further Bethesda assay showed 2.1
BU as low responding inhibitors. Later he was treated
with high dose factor. The family belonged to lower
socioeconomic status and they had another child
with hemophilia. On discharge child was stable and
was advised to come for physiotherapy. The nurse
coordinator played a significant role in educating the
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family members about prevention of injuries, inhibitor
and its management and regular follow-up.
Discussion
Inhibitors make the treatment difficult and complicated
mainly due to financial constraints and the availability
of factors. Inhibitors are diagnosed by activated partial
thromboplastin time (APTT) and confirmatory tests
like Bethesda assay, or Nijmegen method (Verbruggen,
Van Heerde, & Laros-van Gorkom, 2009). Inhibitor
levels are categorized as ‘high titre’ (more than 5
Bethesda Units) or ‘low titre’ (less than 5 Bethesda
Units). ‘Low responding’ and ‘High responding’ is one
of the classifications of inhibitors based on how the
person’s immune system reacts to factor concentrates
(Giuffrida, et al., 2008).
Treatment for a person with the inhibitor is decided
based on inhibitor titre and anamnestic response. We
also need to consider the site and severity of the bleed.
Factor concentrates can be administered at higher doses
and/or more frequent intervals for acute bleeding in
low responders. Acute bleeding in people with high
titre inhibitors are treated with bypassing agents,
such as activated prothrombin complex concentrates
(APCC) and recombinant factor VIIa (Novoseven)
(Franchini & Mannucci, 2011). Factor Eight Inhibitor
Bypassing Agent (FEIBA®) is an example for APCC
which is made from human plasma and contains
variable amounts of clotting factors. This is given once
in eight to twelve hours but should be limited to low
doses such as 100 U/kg per infusion and no more than
200 U/kg/day. Blood clot formation is a risk which has
been associated with excess use of FEIBA. High cost
and unavailability of the treatment products in every
country are the two main difficulties for patients with
inhibitors.
rFVIIa (NovoSeven®) is a synthetic product and
needs to be administered once in two to three hours.
An antifibrinolytic drug such as Tranexamic acid also
can be used for better outcomes. A single-centre,
mixed retrospective and prospective study showed that

Immune tolerance induction therapy was successful
in treating severe hemophilia A patients (Haya, et
al., 2019). Regular rehabilitation program helps the
individuals with inhibitors as they have higher risk for
bleeding. Rehabilitation program needs to be tailored
based on age, joint score and other co-morbidities
(Kubota, et al., 2018).
Conclusion
The inhibitors occur later in life in severe hemophilia
A and their development is generally associated with
a change in bleeding pattern. A range of therapeutic
options to manage the inhibitor is currently available
and comprehensive nursing care is needed to manage
teenagers with inhibitors. They need to be emphasized
on pain management, regular treatment and screening
of inhibitors.
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